RebiDose(TM), the Rebif(R) single use pre-filled pen for MS introduced
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the upcoming introduction of the new device RebiDose(TM), the Rebif(R) single use pre-filled pen, for the self-administration of Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).
"We are pleased to extend our range of devices with RebiDose(TM) to meet the needs of patients looking for simple and minimum injection preparation," said Roberto Gradnik, Head of Global Business Unit Neurodegenerative Diseases at Merck Serono. "The introduction of RebiDose(TM), alongside RebiSmart(TM), which was launched last year, underscores our commitment to improve the treatment convenience of multiple sclerosis patients, by offering them different options to suit their individual injection needs." ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1901